*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Safe Comprehensive Therapy to Prevent Complications in Children with Catarrhal Symptoms Associated with Acute Viral Respiratory Infections: Series of Clinical Cases

Author: KIR'JANOVA V.V, KORZHENEVSKAJA T.B, AKSENOVA N.N
Abstract: Introduction: Ethiopathogenetic medicinal products are included into the active range of therapeutic instruments in the treatment of acute bronchitis in children with acute respiratory viral infection (ARVI). Although using the medicinal products of this group should be strictly regulated and provide a differentiated individual approach with an emphasis to the use of immunocorrective preparations. This article summarizes a number of Clinical Cases of children with catarrhal symptoms of the lower respiratory tract associated with ARVI, received pharmaceutical products and new physiotherapeutic treatment approaches. Results: The new treatment method has demonstrated a good effect and high safety profile in acute bronchitis induced by virus infections, including adenovirus, rhinosyncytial (RS) virus, parainfluenza virus with underlying persistence of Epstein Barr virus (EBV), cytomegalovirus (CMV), S.aureus, S.pneumoniae and other microorganisms in the lower respiratory tract. As a result of therapy the ear nose throat (ENT) and pulmonary catarrhal symptoms were cured in sub- and decompensated dysbiosis of respiratory tract mucus membranes with underlying serum neutropenia, irrespective of etiology and complete blood count parameters. Conclusion: We noted that there were no lower respiratory tract bacterial complications in children with lower respiratory tract catarrhal symptoms associated with ARVI who used initial inhalation administration of the medicinal product based on Interferon Gamma in combination with subsequent narrow-band optical radiation with a wavelength 470 nm (blue light); no delayed or recurrent course of the disease was registered. The comprehensive therapy showed safety and efficacy in patients aged from 7 to 17 years.
Keyword: ARVI, lower respiratory tract catarrhal symptoms, children, Interferon Gamma, inhalations, narrow-band optical radiation with a wavelength 470 nm (blue light)
DOI: https://doi.org/10.31838/ijpr/2021.13.02.284
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free